Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Expands Abroad While Finding Its Way In Its Home Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Takeda announces cross-licensing deals with Dainippon Sumitomo in a rights swap in Europe and Japan that involves ceftaroline and lurasidone.

You may also be interested in...



Takeda To Hunt For New CNS Therapeutics With Heptares' Technology

Making G-Protein coupled receptors in the CNS drugable is the aim of a research collaboration between Takeda and U.K. biotech, Heptares Therapeutics.

Takeda To Hunt For New CNS Therapeutics With Heptares' Technology

Making G-Protein coupled receptors in the CNS drugable is the aim of a research collaboration between Takeda and U.K. biotech, Heptares Therapeutics.

Southwest Japan-heavy Takeda And Dainippon Sumitomo Spared Earthquake Damage, Others May Rebound, But Tokyo Headquarters' Quieted By Rail Disruptions

TOKYO - Offices across Tokyo remained closed Tuesday, stalling the operations of headquarters for many pharma and medical device companies in Japan as the city faced train and highway closures and threats of blackouts through the rest of the week. Meanwhile, stocks for many of the Japanese pharma tumbled on the Nikkei March 14 in response to the emergency at power plants in Fukushima prefecture

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel